BR112013005756A2 - use of anti third party central memory t cells for anti-leukemia/lymphoma treatment - Google Patents

use of anti third party central memory t cells for anti-leukemia/lymphoma treatment

Info

Publication number
BR112013005756A2
BR112013005756A2 BR112013005756-4A BR112013005756A BR112013005756A2 BR 112013005756 A2 BR112013005756 A2 BR 112013005756A2 BR 112013005756 A BR112013005756 A BR 112013005756A BR 112013005756 A2 BR112013005756 A2 BR 112013005756A2
Authority
BR
Brazil
Prior art keywords
cells
individual
central memory
graft
leukemia
Prior art date
Application number
BR112013005756-4A
Other languages
English (en)
Inventor
Reisner Yair
Lask Assaf
Ophir Eran
Or-Geva Noga
Cohen Adva
Afik Ran
Bachar-Lustig Esther
Eidelstein Yaki
Original Assignee
Yeda Research And Development Co. Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research And Development Co. Ltd filed Critical Yeda Research And Development Co. Ltd
Publication of BR112013005756A2 publication Critical patent/BR112013005756A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46434—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

uso de células t de memória central anti partículas estranhas para tratamento antileucemia/linfoma compreende método de tratamento de uma doença em um indivíduo que precisa do mesmo é divulgado; o método compreendendo: (a) transplante de uma célula nãosingênica ou enxerto de tecido ao indivíduo; e (b) administração ao indivíduo dé uma quantidade terapeuticamente eficaz de uma população isolada de células compreendendo doença de enxerto contra hospedeiro (dech) induzindo células antipartículas estranhas tendo um fenótipo de linfócito t (tem) de memória central, as células sendo células de indução de tolerância e capazes de rastreamento aos linfonodos depois do transplante, e adicionalmente caracterizado em que as células são: (i) não-singênicas tanto com o indivíduo quanto com o enxerto; ou (i i) nãosingênicas com o enxerto e singênicas com o indivíduo, assim tratando o indivíduo.
BR112013005756-4A 2010-09-08 2011-09-08 use of anti third party central memory t cells for anti-leukemia/lymphoma treatment BR112013005756A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38071610P 2010-09-08 2010-09-08
US61/380,716 2010-09-08
PCT/IL2011/000727 WO2012032526A2 (en) 2010-09-08 2011-09-08 Use of anti third party central memory t cells for anti-leukemia/lymphoma treatment

Publications (1)

Publication Number Publication Date
BR112013005756A2 true BR112013005756A2 (pt) 2018-12-26

Family

ID=45002090

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013005756-4A BR112013005756A2 (pt) 2010-09-08 2011-09-08 use of anti third party central memory t cells for anti-leukemia/lymphoma treatment

Country Status (15)

Country Link
US (2) US9421228B2 (pt)
EP (1) EP2613801B1 (pt)
JP (1) JP5977238B2 (pt)
KR (1) KR101788826B1 (pt)
CN (2) CN103282047B (pt)
BR (1) BR112013005756A2 (pt)
CA (1) CA2810632C (pt)
ES (1) ES2589678T3 (pt)
HU (1) HUE031063T2 (pt)
IL (1) IL225102A (pt)
MX (1) MX357746B (pt)
PL (1) PL2613801T3 (pt)
PT (1) PT2613801T (pt)
SG (1) SG188473A1 (pt)
WO (1) WO2012032526A2 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010049935A1 (en) 2008-10-30 2010-05-06 Yeda Research And Development Co. Ltd. Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
ES2589678T3 (es) 2010-09-08 2016-11-15 Yeda Research And Development Co. Ltd. Uso de linfocitos T de memoria central anti-terceros para el tratamiento anti-leucemia/linfoma
US20120177621A1 (en) 2011-01-10 2012-07-12 Samuel Strober Enhancement of Allogeneic Hematopoietic Stem Cell Transplantation
SG11201400513PA (en) 2011-09-08 2014-06-27 Yeda Res & Dev Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
JP6142142B2 (ja) * 2012-04-10 2017-06-07 株式会社リンフォテック メモリーｔ細胞を主成分とするリンパ球細胞群の製造方法
CA2991690A1 (en) * 2015-07-16 2017-01-19 Yeda Research And Development Co. Ltd. Genetically modified anti-third party central memory t cells and use of same in immunotherapy
AU2017289879B2 (en) * 2016-06-27 2023-04-20 Yeda Research And Development Co. Ltd. Veto cells generated from memory T cells
US10751368B2 (en) 2017-01-18 2020-08-25 Yeda Research And Development Co. Ltd. Methods of transplantation and disease treatment
US11555178B2 (en) 2017-01-18 2023-01-17 Yeda Research And Development Co. Ltd. Genetically modified veto cells and use of same in immunotherapy
EP3595683A1 (en) * 2017-03-15 2020-01-22 Orca Biosystems, Inc. Compositions and methods for hematopoietic stem cell transplants
MX2022005416A (es) * 2019-11-05 2022-10-18 Yeda Res & Dev Uso de celulas veto en el tratamiento de enfermedades autoinmune mediadas por celulas t.
CA3160296A1 (en) * 2019-11-05 2021-05-14 Yeda Research And Development Co. Ltd. Use of veto cells for the treatment of sickle cell disease

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US5599703A (en) 1993-10-28 1997-02-04 The United States Of America As Represented By The Secretary Of The Navy In vitro amplification/expansion of CD34+ stem and progenitor cells
US6803036B1 (en) 1998-03-03 2004-10-12 University Of Southern California Use of cytokines, cells and mitogens to inhibit graft versus host disease
AU2101600A (en) 1998-12-24 2000-07-31 Novartis Ag Porcine cells incapable of expressing cd40 antigen, for xenotransplantation
US6544506B2 (en) 2000-01-05 2003-04-08 Yeda Research & Development Co. Ltd. Veto cells effective in preventing graft rejection and devoid of graft versus host potential
JP5008810B2 (ja) 2000-04-11 2012-08-22 ユニバーシティ オブ サザン カリフォルニア 抑制性Ｔ細胞を誘導するためにＴＧＦ−βを用いる移植拒絶反応を防止する方法
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
MY137552A (en) 2000-07-03 2009-02-27 Bristol Myers Squibb Co Methods for treating rheumatic diseases using a soluble ctla4 molecule
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
EP1337152A4 (en) 2000-11-30 2004-08-11 Yeda Res & Dev METHODS OF USING CULTURED T CELLS THAT DO NOT INDUCE HOST Graft Reaction (GVHD) TO TREAT DISEASE
ES2302811T3 (es) 2001-05-23 2008-08-01 Bristol-Myers Squibb Company Procedimiento para proteger transplantes de islotes alogenicos usando moleculas mutantes soblules ctla4.
US20030147859A1 (en) 2001-06-18 2003-08-07 Yair Reisner Methods of utilizing cultured hematopoietic progenitor cells for inducing immunological tolerance
CA2534474C (en) 2003-08-04 2014-09-23 Bristol-Myers Squibb Company Methods for treating cardiovascular disease using a soluble ctla4 molecule
WO2005092380A2 (en) 2004-03-26 2005-10-06 Pfizer Products Inc Uses of anti-ctla-4 antibodies
WO2006041763A1 (en) 2004-10-04 2006-04-20 Novartis Ag Renin inhibitors for treating transplantation induced diseases
PT1814580T (pt) 2004-11-24 2016-11-11 Hutchinson Fred Cancer Res Métodos de utilização de il-21 para imunoterapia adotiva e identificação de antigénios tumorais
SI1868635T1 (sl) 2005-04-06 2017-07-31 Bristol-Myers Squibb Company Postopki za zdravljenje imunskih motenj, povezanih s transplantacijo presadkov s topnimi mutiranimi CTLA4 molekulami
EP1928479B1 (en) * 2005-08-24 2016-06-08 Yeda Research And Development Co., Ltd. Universal donor-derived tolerogenic cells for inducing non-syngeneic transplantation tolerance
GB0605217D0 (en) 2006-03-15 2006-04-26 Novartis Ag Method and compositions for assessing acute rejection
GB0606776D0 (en) 2006-04-03 2006-05-10 Novartis Pharma Ag Predictive biomarkers for chronic allograft nephropathy
WO2010019935A2 (en) * 2008-08-15 2010-02-18 Brijen Biotech, Llc Refinery process to produce biofuels and bioenergy products from home and municipal solid waste
US8200915B2 (en) 2008-08-22 2012-06-12 Cadence Design Systems, Inc. Management of very large streaming data sets for efficient writes and reads to and from persistent storage
WO2010049935A1 (en) * 2008-10-30 2010-05-06 Yeda Research And Development Co. Ltd. Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
US20130183322A1 (en) 2010-09-08 2013-07-18 Yeda Research And Development Co., Ltd. Immunosuppressive drug combination for a stable and long term engraftment
ES2589678T3 (es) 2010-09-08 2016-11-15 Yeda Research And Development Co. Ltd. Uso de linfocitos T de memoria central anti-terceros para el tratamiento anti-leucemia/linfoma
SG11201400513PA (en) 2011-09-08 2014-06-27 Yeda Res & Dev Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment

Also Published As

Publication number Publication date
ES2589678T3 (es) 2016-11-15
US9421228B2 (en) 2016-08-23
KR101788826B1 (ko) 2017-10-20
PL2613801T3 (pl) 2016-12-30
EP2613801B1 (en) 2016-06-08
CA2810632A1 (en) 2012-03-15
CN103282047B (zh) 2016-08-24
WO2012032526A2 (en) 2012-03-15
JP2013537187A (ja) 2013-09-30
MX357746B (es) 2018-07-23
JP5977238B2 (ja) 2016-08-24
CN105907713A (zh) 2016-08-31
HUE031063T2 (en) 2017-06-28
CA2810632C (en) 2020-06-02
CN103282047A (zh) 2013-09-04
PT2613801T (pt) 2016-09-12
KR20140030094A (ko) 2014-03-11
WO2012032526A3 (en) 2012-05-18
US20160354410A1 (en) 2016-12-08
MX2013002668A (es) 2013-09-26
EP2613801A2 (en) 2013-07-17
SG188473A1 (en) 2013-05-31
IL225102A (en) 2017-05-29
US20130171108A1 (en) 2013-07-04

Similar Documents

Publication Publication Date Title
BR112013005756A2 (pt) use of anti third party central memory t cells for anti-leukemia/lymphoma treatment
EA202091333A1 (ru) Способы активации, модификации и экспансии t-клеток для лечения рака и связанных с ним злокачественных заболеваний
MX2021012285A (es) Compuestos de piperidina 3-sustituidos para inhibicion del protooncogen-b de linfoma de linea b de casitas (cbl-b) y uso de un inhibidor de cbl-b en combinacion con una vacuna contra el cancer y/o con un virus oncolitico.
BR112016025331A2 (pt) composições antimicrobianas
BR112017004349A2 (pt) terapia com gene de globina para o tratamento de hemoglobinopatias
ES2721180T3 (es) Productos terapéuticos usando células adiposas y secreciones celulares
CR11723A (es) Agente para tratar enfermedad
AR094740A1 (es) Antiadhesión de leucocitos para mitigar los potenciales eventos adversos causados por los dominios de unión específicos de cd3
He et al. MiR-21 is required for anti-tumor immune response in mice: an implication for its bi-directional roles
NZ595331A (en) Ex-vivo treatment of immunological disorders with pkc-theta inhibitors
BR112018003031A2 (pt) formulações clínicas
BR112015027996A8 (pt) Organoides compreendendo células renais isoladas e suas utilizações
BR112015023439A2 (pt) combinação de tratamentos de câncer utilizando micrornas e inibidores egfr-tki
RU2014146170A (ru) Способы лечения диабета и/или улучшения выживания панкреатических островков после трансплантации
MX2016005824A (es) Metodo de cultivo celular.
MX2023004125A (es) Celulas renales bioactivas inmunoprivilegiadas para el tratamiento de enfermedad renal.
BR112017019189A2 (pt) agente terapêutico celular para tratamento de câncer e terapia de combinação com o mesmo
Kretschmer et al. Esophageal squamous cell carcinoma cells modulate chemokine expression and hyaluronan synthesis in fibroblasts
Kogan et al. Exploiting epigenetically mediated changes: acute myeloid leukemia, leukemia stem cells and the bone marrow microenvironment
NZ763301A (en) Adaptation of hollow-fiber-based cell culture technology for the manufacturing of neo-islets or exosomes from stem cells
BR112012026882A2 (pt) sistemas para semear células em sustentações tri-dimensionais
BR112016000874A2 (pt) vírus de rna oncolítico geneticamente estável, método de fabricação e uso dos mesmos
BR112013006004A2 (pt) celulose nano-desagregada
MX2020008415A (es) Metodos y composiciones que actuan de forma selectiva sobre linfocitos treg.
BR112022010072A2 (pt) Métodos que empregam óxido nítrico gasoso para inibir crescimento de tumor

Legal Events

Date Code Title Description
B12F Other appeals [chapter 12.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL